Becker and Duchenne muscular dystrophy: A two-way information process for therapies

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 1, 2014, Pages 5-6

  Lochmüller, Hanns ^a   Bushby, Kate ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ALPHA DYSTROGLYCAN; ANTISENSE OLIGODEOXYNUCLEOTIDE; DYSTROPHIN;

AUTISM; BECKER MUSCULAR DYSTROPHY; BRAIN; CARDIOMYOPATHY; DISEASE SEVERITY; DRUG THERAPY; DUCHENNE MUSCULAR DYSTROPHY; EDITORIAL; EXON SKIPPING; GENE MUTATION; GENE THERAPY; HEART; HEART FAILURE; HUMAN; INTELLECTUAL IMPAIRMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN QUALITY; SKELETAL MUSCLE; STEM CELL TRANSPLANTATION;

EID: 84891824786     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-305193     Document Type: Editorial

References (7)

1. Becker PE, Kiener F. A new x-chromosomal muscular dystrophy. Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr 1955;193: 427-48.
2. Anthony K, Cirak S, Torelli S, et al. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain 2011;134(Pt 12):3547-59.
3. van den Bergen JC, Schade van Westrum SM, Dekker L, et al. Clinical characterisation of Becker muscular dystrophy patients predicts favourable outcome in exon-skipping therapy. J Neurol Neurosurg Psychiatry 2014;85:92-8.
4. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987;51:919-28.
5. Rodino-Klapac LR, Mendell JR, Sahenk Z. Update on the treatment of duchenne muscular dystrophy. Curr Neurol Neurosci Rep 2013;13:332.
6. Jørgensen LH, Larochelle N, Orlopp K, et al. Efficient and fast functional screening of microdystrophin constructs in vivo and in vitro for therapy of duchenne muscular dystrophy. Hum Gene Ther 2009;20:641-50.
7. Harper SQ, Hauser MA, DelloRusso C, et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med 2002;8:253-61. (Pubitemid 34250103)